Annexon (ANNX)
(Delayed Data from NSDQ)
$6.93 USD
-0.06 (-0.86%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $6.92 -0.01 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
ANNX 6.93 -0.06(-0.86%)
Will ANNX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ANNX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANNX
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?
ANNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Annexon (ANNX) This Year?
Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
Other News for ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon reports inducement grants under Nasdaq listing rule
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
Annexon appoints Shikhar Agarwal as SVP, head of commercial